<< Back
Questcor Appoints Gregg Lapointe to Its Board of Directors

UNION CITY, Calif.--(BUSINESS WIRE)--July 6, 2005--Questcor Pharmaceuticals, Inc. (AMEX:QSC), a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders, today announced the appointment of Gregg Lapointe to its Board of Directors.

Mr. Lapointe is Chief Operating Officer of Sigma-Tau Pharmaceuticals, Inc. of Gaithersburg, Maryland. Sigma-Tau Pharmaceuticals is the U.S. subsidiary of Sigma-Tau Finanziaria SpA of Rome, Italy, Questcor's largest shareholder. Mr. Lapointe joined Sigma-Tau in September 2001 as Vice President, Finance. In August 2002, he became Vice President, Operations, and in November 2003 he was elected Chief Operating Officer. Before joining Sigma-Tau, Mr. Lapointe was Vice President, Operations and Vice President, Controller of AstenJohnson, Inc. (formerly JWI Inc.) of Charleston, South Carolina. Mr. Lapointe holds a bachelor's degree in commerce from Concordia University (Montreal, Canada), a graduate diploma in accountancy from McGill University (Montreal, Canada), and a master's degree in business administration from the Fuqua School of Business, Duke University. He is a certified public accountant and a chartered accountant (Canada).

Mr. Lapointe serves on the board of EP Global Communications, Inc., and is a member of the corporate council of the National Organization for Rare Diseases (NORD), the Child Neurology Foundation and Kidney Care Partners.

"We gladly welcome Mr. Lapointe to the Board of Directors of Questcor," said Mr. James L. Fares, President and CEO of Questcor. "Mr. Lapointe brings extensive business experience and skill in the areas of strategic planning, business development, corporate finance and acquisitions. In addition, we are very pleased that with this appointment we now have a representative of Sigma-Tau, our largest shareholder, on our Board of Directors."

About Questcor

Questcor Pharmaceuticals, Inc.(R) (AMEX:QSC) is a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders. Questcor currently markets four products in the U.S.: H.P. Acthar(R) Gel (repository corticotropin injection), an injectable drug that is commonly used for certain neurological conditions; Nascobal(R), the only prescription nasal gel formulation of Cyanocobalamin USP (Vitamin B12), that is approved for patients with B12 deficiency caused by malabsorptive disorders resulting from structural or functional damage, such as bariatric surgery, Crohn's disease and certain neurological conditions; Ethamolin(R) (Ethanolamine Oleate), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; and Glofil-125(R), which is an injectable agent that assesses how well the kidney is working by measuring glomerular filtration rate, or kidney function.

CONTACT: Questcor Pharmaceuticals, Inc.
James L. Fares, 510-400-0700

SOURCE: Questcor Pharmaceuticals, Inc.

Could not find file '\\pro.dianum.io\irwebpro\content3\IRXMLDATA\89\89528\Disclaimers.xml'.